VANCOUVER, BC - MYND Life Sciences Inc. (CSE: MYND) ('MYND'), a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce the formation of its scientific advisory board ('SAB'). The SAB is comprised of international industry experts and pioneers in the fields of neuropsychopharmacology, genetics, immunology, psychedelics, medical research, and clinical trials. 'We are incredibly excited about the roster of advisors we have been able to attract to MYND's scientific advisory board,' stated Dr. Lyle Oberg, MYND's Chief Executive Officer. 'We have continued to believe that the science and patents being advanced and refined by MYND's Dr. Wilfred Jefferies and his team could attract the most pre-eminent and distinguished minds in science from across the globe, and the advisory board we have assembled thus far serves to validate our enthusiasm,' continued Dr. Oberg.

ABOUT MYND LIFE SCIENCES

MYND Life Science Inc. is a leading life sciences company focussed on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on therapeutic approaches to treat diseases of the Central Nervous System using neuroactive agents including psychedelics and other compounds. Research and development is currently underway.

Contact:

Dr. Lyle Oberg

CEO

Email: IR@myndsciences.com

Phone: 954-401-8686

Web: www.myndsciences.com

Forward-Looking Information This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as 'plans', 'expects' or 'does not expect', 'is expected', 'estimates', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

(C) 2021 Electronic News Publishing, source ENP Newswire